FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802172791> ?p ?o ?g. }

• W2802172791 endingPage "1860" @default.
• W2802172791 startingPage "1853" @default.
• W2802172791 abstract "Purpose Capturing patient-reported outcome data is important for evaluating the overall clinical benefits of new cancer therapeutics. We assessed self-reported symptoms of advanced non–small-cell lung cancer in patients treated with osimertinib or chemotherapy in the AURA3 phase III trial. Patients and Methods Patients completed the European Organisation for Research and Treatment of Cancer 13-item Quality of Life Questionnaire-Lung Cancer Module (EORTC QLQ-LC13) questionnaire on disease-specific symptoms and the EORTC 30-item Core Quality of Life Questionnaire (EORTC QLC-C30) on general cancer symptoms, functioning, global health status/quality of life. We assessed differences between treatments in time to deterioration of individual symptoms and odds of improvement (a deterioration or improvement was defined as a change in score from baseline of ≥ 10). Hazard ratios (HRs) were calculated using a log-rank test stratified by ethnicity; odds ratios (ORs) were assessed using logistic regression adjusted for ethnicity. Results At baseline, the questionnaires were completed by 82% to 88% of patients, and 30% to 70% had individual key symptoms. Time to deterioration was longer with osimertinib than with chemotherapy for cough (HR, 0.74; 95% CI, 0.53 to 1.05), chest pain (HR, 0.52; 95% CI, 0.37 to 0.73), and dyspnea (HR, 0.42; 95% CI, 0.31 to 0.58). The proportion of symptomatic patients with improvement in global health status/quality of life was higher with osimertinib (80 [37%] of 215) than with chemotherapy (23 [22%] of 105; OR, 2.11; 95% CI, 1.24 to 3.67; P = .007). Proportions were also higher for appetite loss (OR, 2.50; 95% CI, 1.31 to 4.84) and fatigue (OR, 1.96; 95% CI, 1.20 to 3.22). Conclusion Time to deterioration of key symptoms was longer with osimertinib than with chemotherapy, and a higher proportion of patients had improvement in global health status/quality of life, demonstrating improved patient outcomes with osimertinib." @default.
• W2802172791 created "2018-05-17" @default.
• W2802172791 creator A5001428569 @default.
• W2802172791 creator A5008761149 @default.
• W2802172791 creator A5066717752 @default.
• W2802172791 creator A5071066396 @default.
• W2802172791 creator A5072962250 @default.
• W2802172791 date "2018-06-20" @default.
• W2802172791 modified "2023-10-16" @default.
• W2802172791 title "Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The AURA3 Trial" @default.
• W2802172791 cites W1545248071 @default.
• W2802172791 cites W1947168884 @default.
• W2802172791 cites W1962829821 @default.
• W2802172791 cites W1983651981 @default.
• W2802172791 cites W2008823106 @default.
• W2802172791 cites W2018304470 @default.
• W2802172791 cites W2026342389 @default.
• W2802172791 cites W2035789908 @default.
• W2802172791 cites W2053372579 @default.
• W2802172791 cites W2068394961 @default.
• W2802172791 cites W2068811106 @default.
• W2802172791 cites W2074295444 @default.
• W2802172791 cites W2076178766 @default.
• W2802172791 cites W2080663986 @default.
• W2802172791 cites W2087202287 @default.
• W2802172791 cites W2088540000 @default.
• W2802172791 cites W2091384120 @default.
• W2802172791 cites W2094224904 @default.
• W2802172791 cites W2096092941 @default.
• W2802172791 cites W2096198395 @default.
• W2802172791 cites W2103607521 @default.
• W2802172791 cites W2104389711 @default.
• W2802172791 cites W2109567704 @default.
• W2802172791 cites W2125760261 @default.
• W2802172791 cites W2128385295 @default.
• W2802172791 cites W2132870547 @default.
• W2802172791 cites W2134119471 @default.
• W2802172791 cites W2134235269 @default.
• W2802172791 cites W2154149901 @default.
• W2802172791 cites W2159613453 @default.
• W2802172791 cites W2163351155 @default.
• W2802172791 cites W2167571044 @default.
• W2802172791 cites W2168323778 @default.
• W2802172791 cites W2168434072 @default.
• W2802172791 cites W2171139285 @default.
• W2802172791 cites W2178570731 @default.
• W2802172791 cites W2279027181 @default.
• W2802172791 cites W2333674118 @default.
• W2802172791 cites W2339311613 @default.
• W2802172791 cites W2494292000 @default.
• W2802172791 cites W2560717039 @default.
• W2802172791 cites W2591118779 @default.
• W2802172791 cites W2607954371 @default.
• W2802172791 cites W2760639821 @default.
• W2802172791 cites W2770828094 @default.
• W2802172791 cites W2809455848 @default.
• W2802172791 doi "https://doi.org/10.1200/jco.2017.77.2293" @default.
• W2802172791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29733770" @default.
• W2802172791 hasPublicationYear "2018" @default.
• W2802172791 type Work @default.
• W2802172791 sameAs 2802172791 @default.
• W2802172791 citedByCount "27" @default.
• W2802172791 countsByYear W28021727912019 @default.
• W2802172791 countsByYear W28021727912020 @default.
• W2802172791 countsByYear W28021727912021 @default.
• W2802172791 countsByYear W28021727912022 @default.
• W2802172791 countsByYear W28021727912023 @default.
• W2802172791 crossrefType "journal-article" @default.
• W2802172791 hasAuthorship W2802172791A5001428569 @default.
• W2802172791 hasAuthorship W2802172791A5008761149 @default.
• W2802172791 hasAuthorship W2802172791A5066717752 @default.
• W2802172791 hasAuthorship W2802172791A5071066396 @default.
• W2802172791 hasAuthorship W2802172791A5072962250 @default.
• W2802172791 hasBestOaLocation W28021727912 @default.
• W2802172791 hasConcept C121608353 @default.
• W2802172791 hasConcept C126322002 @default.
• W2802172791 hasConcept C143998085 @default.
• W2802172791 hasConcept C156957248 @default.
• W2802172791 hasConcept C159110408 @default.
• W2802172791 hasConcept C207103383 @default.
• W2802172791 hasConcept C2776256026 @default.
• W2802172791 hasConcept C2776694085 @default.
• W2802172791 hasConcept C2776907518 @default.
• W2802172791 hasConcept C2779951463 @default.
• W2802172791 hasConcept C44249647 @default.
• W2802172791 hasConcept C535046627 @default.
• W2802172791 hasConcept C71924100 @default.
• W2802172791 hasConceptScore W2802172791C121608353 @default.
• W2802172791 hasConceptScore W2802172791C126322002 @default.
• W2802172791 hasConceptScore W2802172791C143998085 @default.
• W2802172791 hasConceptScore W2802172791C156957248 @default.
• W2802172791 hasConceptScore W2802172791C159110408 @default.
• W2802172791 hasConceptScore W2802172791C207103383 @default.
• W2802172791 hasConceptScore W2802172791C2776256026 @default.
• W2802172791 hasConceptScore W2802172791C2776694085 @default.
• W2802172791 hasConceptScore W2802172791C2776907518 @default.
• W2802172791 hasConceptScore W2802172791C2779951463 @default.
• W2802172791 hasConceptScore W2802172791C44249647 @default.

• next